Liver Disease. Is it a big problem? Who is affected What causes it What is required. Community Hepatology Practical tips. Change of Tempo & Style
|
|
|
- Abigail Lewis
- 6 years ago
- Views:
Transcription
1 Liver Disease Is it a big problem? Who is affected What causes it What is required Change of Tempo & Style Community Hepatology Practical tips
2 Transplants ~700 HCC ~3000 Liver Failure ~5000 Deaths ~12000 Recurrent admissions ~50,000 Cirrhosis ~60,000 Alcohol-related disease, NAFLD, Hepatitis C, Chronic liver diseases etc Silently progressing Liver Disease Predictable & Preventable Liver Disease
3
4 Figure 8 : Cause of death ( underlying cause) by age: Average annual proportion of all deaths (by type) in each age group in England, % s th a e D f o e g ta n e rc e P 10% 8% 6% 4% 2% 0% Age Group Alcoholic liver disease Fatty liver disease Liver Cancer Other Chronic liver disease Pancreatitis LFTs or Jaundice Viral Liver Disease Source: ONS mortality data
5 15-34 age group dying of alcoholic liver disease age group dying of alcoholic liver disease
6
7 Chronic Liver Disease (1) Mortality & 2009 Rates per 100,000 population North East 5.7 up to 13.7 North West 7.3 up to 15.2 Yorks & Humber 4.8 up to 10.2 Rapid increase across the country in the last 16 years (1) Metric: Mortality from chronic liver disease including cirrhosis (ICD v10: K70, K73, K74) Source: National Centre for Health Outcomes Development (NCHOD), part of NHS Information Centre Data: SHA level data, standardised for age and gender using European Standard population. Figures are rates per 100,000 population.
8 Mortality from chronic liver disease LA IMD Average Score IMD Rank of Average Score All <75 yrs Months Life Lost omortality from chronic liver disease including cirrhosis (ICD10 K70, K73-K74) odirectly age standardised rates (DSR) o14 of top 20 (70%) LAs' where chronic liver disease results in loss of life are in NW England! Blackpool Isles of Scilly Liverpool Wolverhampton Preston Manchester Wirral Blackburn with Darwen Oldham Burnley Sandwell Hyndburn Halton Salford Newcastle upon Tyne Barrow-in-Furness Lambeth Nottingham Rochdale St. Helens
9 Liver Disease Causes & Risks Obesity or alcohol at hazardous levels 7-12 million Alcohol consumption Obesity (& DM2) Chronic hepatitis B Hepatitis C Systemic inflammatory Congenital/Genetic Adverse medication (Biliary & Pancreatic disease) Alcohol at harmful levels 1-2 million Chronic or significant liver disease 600,000 Non-viral Non-Life style OLT 600
10 Alcohol related liver disease 2,000,000 1,800,000 1,600,000 1,400,000 Alcohol related admissions (NI39) Trends and beyond Public Health Interventions NHS response to Problems & Admissions 1,200,000 1,000,000 ALCOHOL 800, , , , / / / / / / / / / / / / /15 10,000 extra pa 27 extra per day 20 15/ / / / /20 Social behaviours & attitudes Public Policy & regulation
11 Acute 15% Behaviour 21% Chronic 64% (NWPHO) Alcohol-related admissions England 2008/9 Alcohol specific (Acute) Alcohol specific (Chronic) Digestive incl Liver Cancer Other Alcohol specific (Behavioural) Accident/Injury Violence Cardiac (chronic) Hypertens ive (chronic)
12 100% Pattern of deaths in England, by age, in 2007 Total: 500,000 deaths 90% Other Genitourinary 80% 70% Mental Alcohol GI & Liver RESPIRATORY 60% Endocrine SUICIDE CIRCULATORY 50% 40% 30% ACCIDENTAL DEATH Alcohol Alcohol GI cancers 20% Alcohol ALL CANCERS 10% 0% < Source: ONS Death Registry Deaths from mental disorders - For younger people (under 50) - these deaths are mostly people dying from mental/behavioural disorders associated with alcohol or drug use. For older people (over 50) these deaths are almost entirely due to dementia
13 ? Back to France 20 year lag? Next 20 year lag Death due to ALD/Cirrhosis age per 100,000 living in UK
14 288 seats Liver Disease = 1 Dreamliner EVERY WEEK January 1 st until 12 th October Plus one plane every year: PLANE CRASH EVERY SINGLE WEEK FOR A FULL YEAR by 2024!
15 Alcohol and obesity Pint of strong lager = 335 calories Pint of continental lager = 256 calories Pint of cider = 239 calories Large glass of wine = 185 calories Pint of lager = 182 calories Alcopop = 179 calories
16 AFLD, NAFLD and Cirrhosis
17 Football stadia capable of seating all 10 years olds with NAFL 52,000 60,000 76,000 90,000
18 1. Prevent further infections 2. Continue to find undiagnosed cases 3. Get better at offering treatment to diagnosed cases i. Reduce variability (clinical judgement!) ii. Community treatment iii. Prison treatment iv. Engagement services 4. Develop & use more effective treatments 5. More care in treating previous non-svr patients 6. Optimise prevention of premature mortality
19 WHERE ARE WE NOW & WHERE DO WE WANT TO HCV Analysis 2012 Not yet diagnosed SVR (of total) ESLD Deaths Not yet treated - comorbid/esl D Not yet treated - variability? Not yet diagnosed Not yet treated - patient choice Treated non- SVR (of total) ESLD Best 'Ambition' Outcome (Find 90%, Treat 90%, SVR 90%) SVR (of total) Treated non- SVR (of total) Not yet treated - patient choice Deaths
20 What matters to patients? Mortality Survival Experience (incl. trust, safety) Access Information
21 Outcomes Framework Domains
22 NHS Ten steps to address Liver disease Test Assess Conserve Think Refer / Monitor Support Patients & Carers & EOLC LIVER Monitor / Review Rescue events Surveillance for Complication Treat
23 Community Liver Disease Typical GP pop 10,000 (<75yrs=9,210) Expect 88 deaths pa Age <75 dying per annum = 29 Lung Cancer: 2.8 Acute myocardial infarction: 1.6 Breast cancer: 1.8 Liver disease 2.2 Chronic liver disease 60 Established cirrhosis: 6.0 Hepatocellular cancer: 0.6 Dependent drinkers: 640 Risk cirrhosis from NASH: 250 Number with hepatitis C: 40+ Number with hepatitis B: 30+ Total at risk years: >10% Abnormal liver tests if checked: 10*20% Mortality <75 yrs Trends NW Mths M-Heart M-CA lung M-Liver Female Heart Female CA Lung Female Liver
24 Brief Interventions Ryder et al, Nottingham
25
26
27 Thiamine vs. Combined Acamprosate and Disulfiram Thiamine Prescriptions y = x R² = PCT Linear (PCT) Combined Acamprosate and Disulfiram Prescriptions
28 Per capita: Alcohol Consumption ^22% ^14% ^abstention rates Dependent drinkers 1.6m (^24% 10y) Lag time for dependence 10-15yrs 5-7% treatment (US: 10% Low, 15% Med, 20% Hi) GP-BI ASN Spec services Combination
29 Activity upstream reduces costs, reduces the need for complex interventions and improves outcomes Potential for intervention Risk assess Early diagnosis Stop insult Treat Monitor for cancer or complics Treat for cancer or complications incl transplant Liver insult Liver inflammation Liver fibrosis Cirrhosis Consequences of cirrhosis Impact on individual/ health services over time (10-20 years)
30 Reducing Liver Deaths 3,000 Intuitive
31 lives Better secondary care 800 Surveillance for HCC 300 (Transplantation 700+) Hepatitis C 3%...10%pa Chronic Hepatitis B? Obesity strategy
32 Liver Disease: Community Care Assess the risk Alcohol > limits BMI>25, DM, Trigs Immigrant/Ethnic pop Current/Ex PWID Current/Ex Offenders Do the Test ^Liver enzymes Specific Liver disease Incl Cirrhosis (stable) Consider Stage of disease Consider Function Symptoms/Signs Complications Refer Rpt BI s, LFTs Rpt Lifestyle adv etc Test HCV, HBV Liver panel: AA, Igs, B&C, Fn, a1at Monitor, FTs, USS, Bone, OGD Treatment & monitor AE
33 Hepatic Structure & Metabolism
34 Summary: Liver is complex, its clinical management is not! Damage: enzymes (& USS) Function: Bili, Alb, PT (& clinical etc) Fibrosis: (Platelets), P3P, HA, Fibroscan Complications: ascites, haem, enceph
35 Cirrhosis Reduce damage Preserve function Monitor for Liver Failure Alb, Bili, PT Ascites, Jaundice Encephalopathy Portal Hypertension?Varices (OGD 3yrs)?Ascites (weight) HCC USS 6 mthly, AFP
36 10 things to think about in primary care Identify those at risk: (Alc Xs, Obese & DM, Ex- & current PWID, Ethnic groups) Test liver damage: liver enzymes Test liver function: albumen, bilirubin, INR, glucose, urea Test liver fibrosis: platelets Test the liver structure: USS Offer patients information & lifestyle advice Monitor progression of liver disease Watch out for complications: ascites, jaundice, encephalopathy, HCC Refer appropriately: opinion, treatment Always find the explanation for Jaundice!
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
The Cost of Alcohol to the North West Economy Part A
The Cost of Alcohol to the North West Economy Part A May 2012 Foreword Local Authorities are working together across the North West to address the financial and social cost of alcohol harm. We want to
2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital
Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver
2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
Addressing the following six priorities, together with the two national priorities of reducing health inequalities and improving life expectancy,
Dr. Kate Ardern MBChB MSc FFPH Executive Director of Public Health Addressing the following six priorities, together with the two national priorities of reducing health inequalities and improving life
LFTs: an update A MacGilchrist PLIG meeting 31st January 2019
LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant
Liver disease in 2017: challenges and opportunities
Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National
Life After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
Deaths from Suicide and Injury Undetermined
Merseyside Mental Health Equity Audit Interim report on Deaths from Suicide and Injury Undetermined Observatory Report Series No 58 Janet Ubido Liverpool Public Health Observatory April 2004 A report for
Policy Context Perspective from Scotland. Dr Emilia Crighton, Convenor of the Faculty of Public Health Scotland
Policy Context Perspective from Scotland Dr Emilia Crighton, Convenor of the Faculty of Public Health Scotland UK Alcohol Consumption Litres of pure alcohol consumption per capita in the UK 1900-2006 Scots
NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF
NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF Royal Armouries International, Leeds 17 June 2015 17 th Annual Conference of
North West ChiMatters Child and Maternal Health Intelligence Briefing
North West ChiMatters Child and Maternal Health Intelligence Briefing Children with long-term conditions in the North West: Emergency hospital admissions for asthma, diabetes and epilepsy 28/9 March 211
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
Managing abnormal LFTs in Primary care
Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with
The place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
Hepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital
Hepatology cases for the generalist Will Gelson Consultant Hepatologist Addenbrooke s Hospital 30 y o man with upper GI haemorrhage Background heavy alcohol use Hxof 3 pint haematemesis P 100, BP 90/40,
Deaths from liver disease. March Implications for end of life care in England.
National End of Life Care Programme Improving end of life care Deaths from liver Implications for end of life care in England March 212 www.endoflifecare-intelligence.org.uk Foreword The number of people
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
Hepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
Learning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
HCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
Management of Patients with Chronic Hepatitis B: The Alaska Experience
Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts
IMPROVING MENTAL WELLBEING IN ACUTE SETTINGS
IMPROVING MENTAL WELLBEING IN ACUTE SETTINGS Building Bridges and Improving Health in Hospitals Conference, 19th March 2012 Jude Stansfield Mental health & wellbeing Programme Manager Key messages Mental
Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer
Liver Ultrasound - Beyond the Basics Pamela Parker Lead Sonographer Aims Review what we know about the liver Reasons for imaging Focal lesions Diffuse disease Can we do more? The Liver The Liver The Liver
Key Aspects of Diagnosing Alcoholic Hepatitis. Mark Sonderup University of Cape Town & Groote Schuur Hospital
Key Aspects of Diagnosing Alcoholic Hepatitis Mark Sonderup University of Cape Town & Groote Schuur Hospital 42 year old woman, married with 3 children No significant co-morbidities or illnesses Habits
Hepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
Translating clinical trial promise into real world HCV treatment success. Dr K Agarwal Kings College Hospital London
Translating clinical trial promise into real world HCV treatment success Dr K Agarwal Kings College Hospital London Disclosures: BoJo Pharma support: AbbVie/Achillion/ Astellas/ BI/ BMS/ Gilead/ GSK/ Intercept/Janssen/
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
27th January 2016 Getting to Grips with Alcohol
27th January 2016 Getting to Grips with Alcohol 2016 1 Alcohol, Health and the NHS England 2013: 15% of men and 20% of women did not drink any alcohol in the last year. Of those who do drink; 18% of men
Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014
Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV
Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
Hepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
Dental health profile
Oldham Bolton Blackpool Manchester Knowsley Blackburn with Darwen Rochdale Liverpool Lancashire* NORTH WEST Bury Wirral Cumbria Wigan St Helens Halton Tameside Warrington ENGLAND Sefton Trafford Cheshire
Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake
Hepatitis C Request a Test Benefits of testing in AOD services to improve treatment uptake Jenny Bourke Clinical Nurse Specialist Hepatitis C Community Clinic Christchurch About Hepatitis C Hepatitis is
5.2 Main causes of death Brighton & Hove JSNA 2013
Why is this issue important? We need to know how many people are born and die each year and the main causes of their deaths in order to have well-functioning health s. 1 Key outcomes Mortality rate from
Chronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
14. Childhood elective treatments
137 14. Childhood elective treatments 14.1 Drainage of the middle ear (OPCS4: D15) Over 70% of children have at least one episode of glue ear before they are four years old, resulting in short term hearing
4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its
Glyn Halksworth 4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its scale. Or is it? Tourism and alcohol Regional
What can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013
What can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013 The role of the NHS in reducing premature mortality Overview The scale
Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
Conflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
Understanding your FibroScan Results
PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your
Community/GP based screening & management of HBV & HCV
Community/GP based screening & management of HBV & HCV Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial
NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49
Non-alcoholic fatty liver disease (NAFLD): assessment and management NICE guideline Published: 6 July 20 nice.org.uk/guidance/ng49 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
Appendix 1. Innovative risk stratification pathway and standard care
1 Appendix 1. Innovative risk stratification pathway and standard care The current status of standard care In current clinical practice, General Practitioners (GPs) rely upon abnormal liver function tests
Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
Hepatitis C in the North West Report
Hepatitis C in the North West 2014 Report About Public Health England Public Health England s mission is to protect and improve the nation s health and to address inequalities through working with national
Liver Disease. Annual Report. Cardiff and Vale Health Board. April 2016
Liver Disease Annual Report Cardiff and Vale Health Board April 2016 Page 1 of 29 1.0 Executive Summary 1. A full time Hepatologist has been successfully recruited by Cardiff and Vale Health Board. This
Mike Jones. Alcohol Programme Manager GM Public Health Network NHS Greater Manchester
Mike Jones Alcohol Programme Manager GM Public Health Network NHS Greater Manchester Sub-Regional Framework The seven commissions, part of the Association of Greater Manchester Authorities North West Alcohol
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
Hepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
Addiction and Substance misuse pathways
Addiction and Substance misuse pathways Gordon Morse Chief Medical Officer Turning Point UK Gordon Morse statement of interests Sole employer Turning Point Some unpaid advisory work to the Hepatitis C
National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
Liver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities
Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1
POTENTIAL YEARS OF LIFE LOST (PYLL) SOUTH DEVON AND TORBAY 2009 to
SOUTH DEVON AND TORBAY 2009 to 2014 1 Background Potential years of life lost (PYLL) represents the estimated number of potential years not lived by people who die before reaching a given age due to lack
The Liver. Dr Fiona H Gordon Janki Jethwa
The Liver Dr Fiona H Gordon Janki Jethwa A Day in the Life Learning Outcomes Review the physiology of the liver. Understand the effects of alcohol on the liver. Learn how hepatitis c affects the liver.
Update on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
Module 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
Community/GP based screening & management of HBV & HCV
Community/GP based screening & management of HBV & HCV Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial
Map 6: Percentage of people in the National Diabetes Audit (NDA) with Type 1 diabetes receiving all nine key care processes by PCT
78 NHS ATLAS OF VARIATION ENDOCRINE, NUTRITIONAL AND METABOLIC PROBLEMS Map 6: Percentage of people in the National Diabetes Audit (NDA) with Type 1 diabetes receiving all nine key care processes by PCT
DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
Steatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
Management of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
Hepatitis C The NHS Model. Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL
Hepatitis C The NHS Model Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL The NHS Approach Background The strategy Tactics The NHS Approach Background The strategy Tactics NHSE
National Diabetes Audit
National Diabetes Audit Executive Summary Key findings about the quality of care for people with diabetes in England and Wales Report for the audit period 2007-2008 Prepared in partnership with: Executive
EAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
Strategic Framework for Alcohol Harm Reduction in Lancashire
Strategic Framework for Alcohol Harm Reduction in Lancashire 2014 to 2015 Contents Page/s Working in Partnership to Address Alcohol Harm Reduction 3 Strategy Summary 6 Action Plan Summary 7 Section 1 Purpose
What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured
What Is Cirrhosis? Cirrhosis occurs when the liver is permanently scarred or injured by chronic conditions and diseases. Common causes of cirrhosis include: Long-term alcohol abuse. Chronic viral hepatitis
The Blue Light project: The story. A report on progress to March 2016
The Blue Light project: The story so far A report on progress to March 2016 The Blue Light project is an innovative and cost effective approach to tackling one of the most challenging groups in the community:
March 2012: Review September 2012
10. Cancer This section of the JSNA explores the incidence, prevalence, mortality and survival rates of cancer, to inform target setting and commissioning. Approximately 1200 Trafford residents are diagnosed
NAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
British Liver Transplant Group Pathology meeting September Leeds cases
British Liver Transplant Group Pathology meeting September 2014 Leeds cases Leeds Case 1 Male 61 years Liver transplant for HCV cirrhosis with HCC in January 2014. Now raised ALT and bilirubin,? acute
EVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities
Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1
Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia
Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia Hye Kyung Chang, Jung-Tak Oh, Seung Hoon Choi, Seok Joo Han Division of Pediatric Surgery, Department of Surgery, Yonsei
Review: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
Commissioning for Value Focus Pack. CCG: Heywood, Middleton & Rochdale Focus Area : Mental Health Programme Budget Category
Commissioning for Value Focus Pack CCG: Heywood, Middleton & Rochdale Focus Area : Mental Health Programme Budget Category What is a Deep Dive pack? CCGs have received a bespoke Commissioning for Value
Focus on alcohol. A guide to drinking and health
Focus on alcohol A guide to drinking and health Many of us enjoy a drink when at home or out with friends, but alcohol is a powerful drug and we need to be careful how we use it. Drinking too much can
Non Alcohol Fatty Liver Disease (NAFLD) An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Non Alcohol Fatty Liver Disease (NAFLD) An information guide Non Alcohol Fatty Liver Disease (NAFLD) What is Non Alcohol Fatty Liver Disease?
At Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
CIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
Public Health Intelligence Section Preston Primary Care Trust. April 05
Alcohol-related death rates in Preston Local Authority and Preston Primary Care Trust, 2001 to 2004 Farha Abbas, Public Health Research & Intelligence Analyst Jonathan Peters, Public Health Information
Scotland s Action Plan on Hepatitis C. Dr. Norah Palmateer CATIE Forum 2015, Making it work: From planning to practice Toronto, 15 th October 2015
Scotland s Action Plan on Hepatitis C Dr. Norah Palmateer CATIE Forum 2015, Making it work: From planning to practice Toronto, 15 th October 2015 Outline Background Scotland s Action Plan on Hepatitis
Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford
Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions
Understanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
PROGRAMME AT A GLANCE
PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver